Incretin Analogs for Weight Management in Adults Without Diabetes
Recommended Citation
Lobkovich A, Kale-Pradhan P, and Lipari M. Incretin Analogs for Weight Management in Adults Without Diabetes. Ann Pharmacother 2023.
Document Type
Article
Publication Date
7-31-2023
Publication Title
The Annals of pharmacotherapy
Abstract
OBJECTIVE: This is a narrative review of incretin analogs and their effect on weight management in adult without diabetes.
DATA SOURCES: Randomized controlled trials were identified by English language. PubMed/MEDLINE, Scopus, and Embase databases were searched from inception through June 2023 to identify all pertinent trials reporting outcomes on efficacy and safety search using the terms: tirzepatide, semaglutide, liraglutide, and obesity.
STUDY SELECTION AND DATA EXTRACTION: Selected studies were included if the study population was composed of adults without diabetes being treated by glucagon-like peptide 1 (GLP-1) receptor agonists or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists for weight management, and weight loss was assessed as a primary outcome.
DATA SYNTHESIS: Fifteen studies involving 3 pharmacotherapies (liraglutide, semaglutide, and tirzepatide) were identified. Efficacy data supporting the use of these agents for weight management were promising when compared to placebo and/or other behavioral therapies. Percent weight loss ranged from 5.7% to 11.8%, 14.9% to 17.4%, and 15% to 20.9% for liraglutide, semaglutide, and tirzepatide, respectively. Safety data were relatively similar across all trials and identified gastrointestinal adverse effects as most common.
RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Glucagon-like peptide 1 agonists are preferred for overweight or obese patients by the American Gastroenterological Association. Future guidelines may address tirzepatides' place in therapy as new evidence comes forth. Providers should consider patient-specific factors such as cost, adverse effects, drug interactions, and comorbidities when prescribing these agents and provide education regarding the need for concurrent diet and exercise modifications.
CONCLUSIONS: All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.
PubMed ID
37522468
ePublication
ePub ahead of print
First Page
10600280231190089
Last Page
10600280231190089
